Level of chromosomal abnormality in lung cancer may predict immunotherapy response
Iran enforces 10-day lockdown amid fourth wave of pandemic
11 April 2021Brazil now has more young than old COVID patients in ICUs
11 April 2021Level of chromosomal abnormality in lung cancer may predict immunotherapy response
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy—an abnormal number of chromosomes—tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.
